8 unchanged sentences
and AstraZeneca AB, dated as of October 20, 2014.
+Added: Share Purchase Agreement by and among AstraZeneca Treasury Limited, FibroGen China Anemia Holdings, Ltd., and FibroGen, Inc., dated as of February 20, 2025.
+Added: Amendment No.1 to the First Amended and Restated Evaluation Agreement, by and between Fortis Therapeutics, Inc.
+Added: and FibroGen, Inc., dated as of March 28, 2025.
+Added: Amendment No.1 to the First Amended and Restated Option Agreement and Plan of Merger, by and between Fortis Therapeutics, Inc.
+Added: and FibroGen, Inc., dated as of March 28, 2025.
+Added: First Amendment to Financing Agreement, by and among FibroGen, Inc., NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II ESC Fairview Holding LLC, and Wilmington Trust, National Association, dated as of May 8, 2025.
Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).
10 unchanged sentences
FibroGen, Inc.
−Removed: November 12, 2024
/s/ Thane Wettig
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 12, 2024
−Removed: /s/ Juan Graham
+Added: /s/ David DeLucia
+Added: David DeLucia
Senior Vice President and Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.